RECRUITING

Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a split-face, single-blind study assessing the use of an antioxidant serum with a series of acne laser treatments to reduce sebum production in healthy male and female subjects between the ages of 18 and 65 years, inclusive, with Fitzpatrick skin types I-VI.

Official Title

A Split-Face, Single-Blind, Study Assessing the Use of a Topical Antioxidant Containing Silymarin With A Series of 1726nm Laser Procedures to Reduce Sebum Production

Quick Facts

Study Start:2024-04-24

Study Completion:2025-04-24

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06376110

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Healthy male and female subjects aged between 18 and 65 years, inclusive of all Fitzpatrick Skin Types (I-VI) 2. Self-perceived "oily skin". Subject must answer "Yes" to the question "Do you have an oily complexion?" 3. Mild to moderate acne (2-3) based on IGA 4. No known medical conditions that, in the Investigator's opinion may interfere with study participation 5. Female subjects of childbearing potential must be on and remain on a study-specified stable form of birth control throughout participation in study (See Section 6.1.1) 6. Willingness to cooperate and participate by following study requirements 7. Individuals must sign an informed consent and a photography consent	1. Subjects that are being treated for cancer or have a history of facial skin cancer on the test areas 2. Subjects with sunburn, moderate to pronounced suntan, pronounced asymmetric skin aging, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results 3. Subjects currently taking certain medications which in the opinion of the Investigators may interfere with the study. This includes but not limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids \[steroid nose drops, inhalers and/or eye drops are permitted\]), and immunosuppressive drugs 4. Subjects with self-reported, uncontrolled systemic disease which, in the opinion of the Investigator, may hinder either the subject 's ability to perform all responsibilities of the trial or the Investigator's ability to perform assessments 5. Females known to be pregnant, nursing or planning to become pregnant 6. Subjects participating in other facial clinical studies 7. Subjects who have routinely used an alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks or Retin-A, Retin-A Micro, Renova ,Differin , Avita, Tazorac, or Soriatane within 8 weeks of the study start or have taken Accutane within one year of the study start. Subjects who have used Retinol in the last 8 weeks 8. Subjects with history of severe acne flares 9. Subjects who have had ablative laser treatments, microneedling, and/or chemical peels or dermabrasion within the last six months 10. Subjects who have had non-ablative laser treatments or IPL within the last 3 months 11. Subjects with known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs 12. Subjects currently using topically applied prescription medications on the face

Inclusion Criteria

Exclusion Criteria

1. Healthy male and female subjects aged between 18 and 65 years, inclusive of all Fitzpatrick Skin Types (I-VI)
2. Self-perceived "oily skin". Subject must answer "Yes" to the question "Do you have an oily complexion?"
3. Mild to moderate acne (2-3) based on IGA
4. No known medical conditions that, in the Investigator's opinion may interfere with study participation
5. Female subjects of childbearing potential must be on and remain on a study-specified stable form of birth control throughout participation in study (See Section 6.1.1)
6. Willingness to cooperate and participate by following study requirements
7. Individuals must sign an informed consent and a photography consent

1. Subjects that are being treated for cancer or have a history of facial skin cancer on the test areas
2. Subjects with sunburn, moderate to pronounced suntan, pronounced asymmetric skin aging, tattoos, scars or other disfiguration, dilated vessels or other conditions on the test area that might influence the test results
3. Subjects currently taking certain medications which in the opinion of the Investigators may interfere with the study. This includes but not limited to routine high dosage use of anti-inflammatory drugs (aspirin, ibuprofen, corticosteroids \[steroid nose drops, inhalers and/or eye drops are permitted\]), and immunosuppressive drugs
4. Subjects with self-reported, uncontrolled systemic disease which, in the opinion of the Investigator, may hinder either the subject 's ability to perform all responsibilities of the trial or the Investigator's ability to perform assessments
5. Females known to be pregnant, nursing or planning to become pregnant
6. Subjects participating in other facial clinical studies
7. Subjects who have routinely used an alpha-hydroxy-acid (AHA) or a beta-hydroxy-acid (BHA) containing product within two weeks or Retin-A, Retin-A Micro, Renova ,Differin , Avita, Tazorac, or Soriatane within 8 weeks of the study start or have taken Accutane within one year of the study start. Subjects who have used Retinol in the last 8 weeks
8. Subjects with history of severe acne flares
9. Subjects who have had ablative laser treatments, microneedling, and/or chemical peels or dermabrasion within the last six months
10. Subjects who have had non-ablative laser treatments or IPL within the last 3 months
11. Subjects with known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs
12. Subjects currently using topically applied prescription medications on the face

Contacts and Locations

Study Contact

Alexsandra Scholler, BS

CONTACT

5122792545

iitcoordinator@atxresearch.com

Celeste Katona, BA

CONTACT

5122792545

ckatona@atxresearch.com

Principal Investigator

Edward Lain, MD, MBA

PRINCIPAL_INVESTIGATOR

Austin Institute for Clinical Research

Study Locations (Sites)

Austin Institute for Clinical Research, Inc.

Pflugerville, Texas, 78660

United States

Collaborators and Investigators

Sponsor: Austin Institute for Clinical Research

Edward Lain, MD, MBA, PRINCIPAL_INVESTIGATOR, Austin Institute for Clinical Research

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-04-24

Study Completion Date2025-04-24

Study Record Updates

Study Start Date2024-04-24

Study Completion Date2025-04-24

Terms related to this study

Additional Relevant MeSH Terms

Acne